INmune Bio's INKmune™ Advances to Third Dose-Escalation Cohort in Clinical Trials

INmune Bio's INKmune™ Advances to Third Dose-Escalation Cohort in Clinical Trials

INmune Bio Inc. has announced the progression of their innovative cancer treatment, INKmune™, into the third dose-escalation cohort of its clinical trials. This advancement follows successful outcomes from the second cohort, with the third cohort set to commence in approximately 30 days. The doses in the second and third cohorts are three and five times greater than those in the first cohort, respectively. With all eight clinical sites now operational, additional results from these higher dose cohorts are anticipated soon.

Understanding INKmune™

INKmune™ is a cutting-edge, pharmaceutical-grade therapy that transforms resting natural killer (NK) cells into tumor-killing memory-like NK cells (mlNK cells). Unlike traditional treatments, INKmune™ does not necessitate pre-medication or cytokine therapy. It is administered via a simple intravenous infusion, making it a patient-friendly option. The treatment has shown efficacy in various NK-resistant tumors, including leukemia, lymphoma, and several solid tumors such as lung and breast cancer. Currently, INKmune™ is being evaluated in an open-label Phase I/II trial for metastatic castration-resistant prostate cancer in the United States.

About INmune Bio Inc.

INmune Bio Inc. is a clinical-stage biotechnology company that specializes in therapies targeting the innate immune system to combat diseases. With two primary product platforms in clinical trials, the company is at the forefront of innovative treatment development. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform aims to neutralize soluble TNF, addressing conditions like cancer, Alzheimer's disease, and treatment-resistant depression. The Natural Killer Cell Priming Platform, featuring INKmune™, focuses on eliminating minimal residual disease in cancer patients. INmune Bio’s precision medicine approach is pivotal in treating a wide array of hematologic and solid tumor malignancies.

Forward-Looking Statements

The clinical trials involving INKmune™ and other products such as INB03™ and XPro™ are in early stages, and there is no guarantee of specific outcomes. The forward-looking statements in this release are based on current expectations and entail risks and uncertainties that could lead to different actual results. These include the company’s ability to produce sufficient drug quantities for trials, secure additional funding, and achieve regulatory approvals. Further information is available in INmune Bio’s filings with the Securities and Exchange Commission.

For more information, visit INmune Bio's website.

Contact Information

INmune Bio Contact: David Moss, CFO Phone: (858) 964-3720 Email: info@inmunebio.com

Investor Contact: Mike Moyer, Managing Director – LifeSci Advisors Email: mmoyer@lifesciadvisors.com